Roche (OTCQX:RHHBY) announced today that it appointed Brad Moore as president and CEO of Roche Diagnostics North America.
Indianapolis-based Roche Diagnostics North America said Moore’s appointment becomes effective Jan. 1, 2023. He currently serves as SVP of core lab and point of care within Roche Diagnostics North America. He succeeds and reports to Matt Sause, whom Basel, Switzerland-based Roche recently named CEO of its global diagnostics business.
“Brad has a proven reputation for delivering outstanding results and is a highly effective leader,” said Sause. “I’m confident his experience will be a tremendous asset for the North America team, our customers and patients.”
Moore joined the company in October 2016. He initially joined as head of the company’s North American diabetes care business. In 2019, his role expanded to include Europe and North America commercial operations. That included mature markets in Europe, the U.S., Canada, Australia and New Zealand, all within the diabetes care arm.
In 2020, Moore took over as SVP of core lab and point ofc care within the newly created core lab and point of care business unit.
Roche has seen a slew of personnel changes around the top of its diagnostic business recently. The appointment of Sause to the corner office and to the company’s executive committee becomes effective Jan. 1, 2023.
The company appointed current Roche Diagnostics CEO Thomas Schinecker to CEO of the entire organization, effective March 15, 2023.